Iambic Therapeutics’ Executives Plow $0‑Valued Options Into Stock, Betting Big on AI‑Driven Oncology Growth After IPO
Insiders of Iambic Therapeutics just bought shares post‑IPO, signaling confidence in its AI‑driven oncology platform and potential upside for investors.
4 minutes to read